A biotech stock focused on GLP-1 could challenge Novo Nordisk.

Even if you might not fully understand what it means in a technical sense, you’ve probably heard of Novo Nordisk’s (NYSE: NVO) medicines like Ozempic and Wegovy. These drugs have been tremendously…

Read More: https://www.fool.com/investing/2024/08/25/this-glp-1-biotech-stock-could-give-novo-nordisk-a/?source=iedfolrf0000001